Valion Bio, Inc.
VBIO · XNASCIK 1787740fmd_1SZ97CN3Z3DDBHCFE4VCSQSGM3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 1 | 1 | – |
| Cost of revenue | 1 | 2 | 1 | 1 | – |
| Net interest income | (2) | 0 | 0 | 0 | – |
| Gross profit | (0) | 0 | 0 | 0 | – |
| Research and development | 1 | 2 | 2 | 1 | 3 |
| Selling, general and administrative | 5 | 9 | 7 | 3 | 5 |
| Total operating expenses | 6 | 10 | 9 | 4 | 8 |
| Operating income | (6) | (10) | (8) | (4) | (8) |
| Interest expense | – | – | – | 0 | 0 |
| Interest and investment income | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (3) | 0 | 0 | 0 | (0) |
| Income before taxes | – | (10) | (8) | – | 9 |
| Income tax expense | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | (4) | (8) |
| Net income | (8) | (10) | (8) | (6) | (9) |